Investigational Drug Information for Ladarixin
What is the drug development status for Ladarixin?
Ladarixin is an investigational drug.
There have been 8 clinical trials for Ladarixin.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 21st 2020.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 1, Diabetes Mellitus, and Lung Neoplasms. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, NYU Langone Health, and [disabled in preview].
There are forty US patents protecting this investigational drug and forty-nine international patents.
Summary for Ladarixin
| US Patents | 40 |
| International Patents | 49 |
| US Patent Applications | 84 |
| WIPO Patent Applications | 15 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 2 (2020-12-21) |
| Vendors | 37 |
Recent Clinical Trials for Ladarixin
| Title | Sponsor | Phase |
|---|---|---|
| Ladarixin With Sotorasib in Advanced NSCLC - Phase II | NYU Langone Health | Phase 2 |
| Ladarixin With Sotorasib in Advanced NSCLC - Phase I | NYU Langone Health | Phase 1 |
| Randomized, Double-blind, Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. | Dompé Farmaceutici S.p.A | Phase 2 |
Clinical Trial Summary for Ladarixin
Top disease conditions for Ladarixin
Top clinical trial sponsors for Ladarixin
US Patents for Ladarixin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ladarixin | ⤷ Start Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Start Trial |
| Ladarixin | ⤷ Start Trial | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 | Syntrix Biosystems Inc. (Auburn, WA) | ⤷ Start Trial |
| Ladarixin | ⤷ Start Trial | Oral drug dosage form comprising various release profiles | Triastek Inc | ⤷ Start Trial |
| Ladarixin | ⤷ Start Trial | Method of treating C3 glomerulopathy | Chemocentryx Inc | ⤷ Start Trial |
| Ladarixin | ⤷ Start Trial | Prevention and treatment of diabetic nephropathy | Dompe Farmaceutici SpA , Boston Childrens Hospital | ⤷ Start Trial |
| Ladarixin | ⤷ Start Trial | Anti-CXCR2 antibodies and uses thereof | Cephalon LLC | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ladarixin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ladarixin | Australia | AU2017261372 | 2036-05-05 | ⤷ Start Trial |
| Ladarixin | Canada | CA3023278 | 2036-05-05 | ⤷ Start Trial |
| Ladarixin | China | CN107847398 | 2036-05-05 | ⤷ Start Trial |
| Ladarixin | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Start Trial |
| Ladarixin | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Start Trial |
| Ladarixin | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
